Distinct Biology Driving Different Treatment Needs: Advances in genomic profiling reveal that pediatric leukemias are ...

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

Allogeneic HSCT is frequently complicated by acute GVHD (~50%) and chronic GVHD (30%–70%), with steroid-refractory disease representing a major unmet need despite ruxolitinib availability. CK0802 ...

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in ...

FDA‑approved zongepanib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

Sabari, MD, discusses the depth and durability of response to zongertinib in patients with HER2 mutation–positive non–small ...

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for ...

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with ...

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

A single cilta-cel infusion after fludarabine/cyclophosphamide produced 100% MRD negativity at 10⁻⁶ by month 2, sustained at ...

As advanced therapies continue to move beyond academic medical centers, the success of this transition will increasingly ...

Pelareorep combined with FOLFIRI and bevacizumab produced a 19.5-month median duration of response and 33% ORR in second-line ...